Skip to main content

Table 6 Patients experiencing AEs

From: Treatment of migraines with Tianshu capsule: a multi-center, double-blind, randomized, placebo-controlled clinical trial

EventTSC (N = 750)Placebo (N = 250)P values
Adverse events, number of patients with event, no. (%)24 (3.20%)8 (3.20%)1.0000
Possibly drug-related adverse events, no. (%)9 (1.20%)2 (0.80%)0.7404
 gastrectasia1 (0.13%)0
 stomach ache1 (0.13%)0
 abdominal tympany2 (0.27%)1 (0.40%)
 dizziness2 (0.27%)0
 conjunctival congestion1 (0.13%)0
 epistaxis1 (0.13%)1 (0.40%)
 menometrorrhagia1 (0.13%)0
Adverse events resulting in experiment discontinuation, no. (%)1 (0.10%)1 (0.40%)0.4377
 epigastric pain1 (0.10%)0
 allergy with stomach ache01 (0.40%)
Serious adverse events, no. (%)00−/−